Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 27, 2024
Today marks a significant milestone as the Bill & Melinda Gates Foundation (BMGF) announces a new Open Access policy, representing a departure from traditional practices. This policy will cease support for individual article publishing fees, known as APCs, and mandate the use of preprints while advo...
Blog Post
October 24, 2023
I was thrilled when I read last week that Claudia Goldin had won the Nobel Prize in Economics. I have never met her but you could say I discovered her 20 years ago when her 2003 study with Lawrence Katz entitled “The Power of the Pill: Oral Contraceptives and Women’s Career and Marriage Decisions” w...
Blog Post
October 11, 2023
Budget support offers direct financing to a country’s treasury to create more “fiscal space” for public programs. It has constituted some 14 percent of ODA on average, increasing to over 20 percent in times of crisis. No aid modality is more controversial. Critics argue that, without earmarking fund...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 22, 2023
The IMF has now approved ten new loans to countries under its new Resilience and Sustainability Trust (RST), established in 2022 to provide financial support on concessional terms to countries facing long-term structural challenges arising from two key threats: climate change and pandemic preparedne...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...